Login / Signup

Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.

Yuichiro IwamotoTomohiko KimuraKazunori DanHideyuki IwamotoJunpei SanadaYoshiro FushimiYukino KatakuraMasashi ShimodaYuka NogamiYoshiko ShirakiyaShuhei NakanishiTomoatsu MuneKohei KakuHideaki Kaneto
Published in: Diabetes, obesity & metabolism (2024)
The combination therapy with the DPP-4 inhibitor anagliptin and the SGLT2 inhibitor luseogliflozin inhibits fat deposition in the liver via anti-inflammatory effects during the early phase of diet-induced liver steatosis.
Keyphrases
  • high fat diet
  • combination therapy
  • adipose tissue
  • insulin resistance
  • high fat diet induced
  • metabolic syndrome
  • type diabetes